ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1825/S. 2821 PSA Screening for HIM Act; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| JONATHAN OEHMEN | — |
| STEPHEN RUBRIGHT | — |
Health Issues HCR
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| JONATHAN OEHMEN | — |
| STEPHEN RUBRIGHT | — |
Copyright/Patent/Trademark CPT
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| JONATHAN OEHMEN | — |
| STEPHEN RUBRIGHT | — |
Insurance INS
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act; Issues related to Eye Screening and Access (no specific bills).
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| JONATHAN OEHMEN | — |
| STEPHEN RUBRIGHT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.